Cambridge, USA-based Vesalius Therapeutics has entered into a multi-target strategic alliance with the UK’s GSK to discover ...
Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...
GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...
GSK celebrates 100 years in India with former MDs, highlighting resilience and reinvention in the pharmaceutical industry.
GSK Pharmaceuticals India focuses on affordable general medicine access amidst premiumisation trend, discussed by managing ...
GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...
As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...
GlobalData on MSN1d
Are dry powder inhalers the key to sustainable respiratory care?Though prescribing climate-friendly dry powder inhalers is environmentally sound, some experts warn certain patients may be ...
GSK has spent slightly more on lobbying this year compared with 2023. The company spent $3.87 million in the first three ...
While generics may dominate due to cost advantages and meeting needs of a developing economy, there is a growing thrust ...
Royalty Pharma's Q3 results show growth driven by strong portfolio performance and acquisitions. See why we recommend a buy ...
Emily Field from Barclays and Lance Wilks share insights on how RFK Jr.'s influence could affect stocks in the pharmaceutical and healthcare sectors, including companies like GSK, Sanofi, and Novo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback